David is a solicitor with experience across a variety of areas of intellectual property practice, including patents, designs, trade marks and passing off. He joined Dehns in 2022.
As a former pharmaceutical research scientist, David has a particular interest in contentious and non-contentious patent and regulatory matters affecting the life sciences sector. He has also assisted clients with patent opinions, freedom to operate and validity assessments and issues concerning pharmaceutical product lifecycle management.
David handles IP work for clients ranging from individuals and small start-up companies to major multinationals. In addition to contentious matters, David also advises on licensing and contractual agreements relating to the development and exploitation of intellectual property rights.
Prior to qualifying as a lawyer, David spent over a decade as a pharmaceutical research scientist at clinical centres in London (King’s College London), Paris (INSERM) and New York (NYU Medical Centre), before leading a neuroscience pre-clinical drug discovery team at GlaxoSmithKline.
David was previously on secondment in Beijing and Hong Kong for several years and has assisted clients with enforcement strategy in China and Southeast Asia.
Horsham Nutraceuticals Ltd & Anor v Manna Pro Products LLC  EWHC 1935 (Ch)
Glew & Ors v Amro Biotech & Ors  EWHC 3183 (Ch)
Icescape Ltd. V Ice-World International BV  Civ 2219
Fontem Holdings 1BV v Ten Motives Ltd  EWHC 2752 (Pat)
ViiV Healthcare Ltd v Teva UK Ltd  EWHC 1074 (Ch)